45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
88,358
Insurances with rates
35
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 51905029-2255347 | 30237-8900-06 - sipuleucel-T - Susp | $2,368,795 | $639,575 | — | — | 9 |
| 51905029-2255347 | 30237-8900-06 - sipuleucel-T - Susp | $2,368,795 | $639,575 | — | — | 13 |
| 109228707-2255347 | 00310-4535-30 - tremelimumab actl 20 mg/mL Soln | $1,302,724 | $351,735 | — | — | 9 |
| 109228707-2255347 | 00310-4535-30 - tremelimumab actl 20 mg/mL Soln | $1,302,724 | $351,735 | — | — | 13 |
| 108290516-2255347 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $1,034,029 | $279,188 | — | — | 9 |
| 108290516-2255347 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $1,034,029 | $279,188 | — | — | 13 |
| 108290269-2255347 | 79952-0110-01 - loncastuximab tesirine 10 mg Injec | $879,735 | $237,529 | — | — | 9 |
| 108290269-2255347 | 79952-0110-01 - loncastuximab tesirine 10 mg Injec | $879,735 | $237,529 | — | — | 13 |
| 1287035-2255347 | 76128-0155-75 - porfimer 75. mg REC Injection | $819,940 | $221,384 | — | — | 9 |
| 1287035-2255347 | 76128-0155-75 - porfimer 75. mg REC Injection | $819,940 | $221,384 | — | — | 13 |
| 108503656-2255347 | 72493-0103-03 - mitoMYcin 40 mg Kit | $791,762 | $213,776 | — | — | 9 |
| 108503656-2255347 | 72493-0103-03 - mitoMYcin 40 mg Kit | $791,762 | $213,776 | — | — | 13 |
| 108819334-2255347 | 00008-0100-01 - inotuzumab ozogamicin 0.9 mg Powde | $742,736 | $200,539 | — | — | 9 |
| 108819334-2255347 | 00008-0100-01 - inotuzumab ozogamicin 0.9 mg Powde | $742,736 | $200,539 | — | — | 13 |
| 108087544-2255335 | 67979-0002-01 - histrelin 50 mg Implan | $661,132 | $178,506 | — | — | 9 |
| 108087544-2255335 | 67979-0002-01 - histrelin 50 mg Implan | $661,132 | $178,506 | — | — | 13 |
| 108963946-2255335 | 69866-1025-01 - autologous cultured chondrocytes 0 | $637,459 | $172,114 | — | — | 9 |
| 108963946-2255335 | 69866-1025-01 - autologous cultured chondrocytes 0 | $637,459 | $172,114 | — | — | 13 |
| 108963947-2255335 | 69866-1030-05 - autologous cultured chondrocytes i | $637,459 | $172,114 | — | — | 9 |
| 108963947-2255335 | 69866-1030-05 - autologous cultured chondrocytes i | $637,459 | $172,114 | — | — | 13 |
| 108978003-2255335 | 69866-1030-08 - autologous cultured chondrocytes 1 | $637,459 | $172,114 | — | — | 9 |
| 108978003-2255335 | 69866-1030-08 - autologous cultured chondrocytes 1 | $637,459 | $172,114 | — | — | 13 |
| 108031526-2255347 | 50242-0105-01 - polatuzumab vedotin 140 mg Powder | $585,993 | $158,218 | — | — | 9 |
| 108031526-2255347 | 50242-0105-01 - polatuzumab vedotin 140 mg Powder | $585,993 | $158,218 | — | — | 13 |
| 108815520-2255347 | 00003-7125-11 - nivolumab-relatlimab rmbw 240 mg-8 | $485,430 | $131,066 | — | — | 9 |
| 108815520-2255347 | 00003-7125-11 - nivolumab-relatlimab rmbw 240 mg-8 | $485,430 | $131,066 | — | — | 13 |
| 1284898-2255347 | 48818-0001-02 - PRALAtrexate Soln | $471,134 | $127,206 | — | — | 9 |
| 1284898-2255347 | 48818-0001-02 - PRALAtrexate Soln | $471,134 | $127,206 | — | — | 13 |
| 1288090-2255347 | 00024-5824-11 - cabazitaxel Soln | $463,273 | $125,084 | — | — | 9 |
| 1288090-2255347 | 00024-5824-11 - cabazitaxel Soln | $463,273 | $125,084 | — | — | 13 |
| 108927364-2255347 | 50242-0245-01 - pertuzumab-trastuz-hyaluron-zzxf 1 | $437,188 | $118,041 | — | — | 9 |
| 108927364-2255347 | 50242-0245-01 - pertuzumab-trastuz-hyaluron-zzxf 1 | $437,188 | $118,041 | — | — | 13 |
| 102537516-2255347 | 66302-0014-01 - dinutuximab 17.5 mg/5 mL Soln | $395,921 | $106,899 | — | — | 9 |
| 102537516-2255347 | 66302-0014-01 - dinutuximab 17.5 mg/5 mL Soln | $395,921 | $106,899 | — | — | 13 |
| 53132921-2255347 | 00074-3473-03 - leuprolide 45 mg/6 months Powder | $382,153 | $103,181 | — | — | 9 |
| 53132921-2255347 | 00074-3473-03 - leuprolide 45 mg/6 months Powder | $382,153 | $103,181 | — | — | 14 |
| 109148167-2255347 | 00173-0898-03 - dostarlimab gxly 500 mg/10 mL Soln | $378,671 | $102,241 | — | — | 9 |
| 109148167-2255347 | 00173-0898-03 - dostarlimab gxly 500 mg/10 mL Soln | $378,671 | $102,241 | — | — | 13 |
| 1278993-2255347 | 51144-0050-01 - brentuximab vedotin REC Injection | $378,052 | $102,074 | — | — | 9 |
| 1278993-2255347 | 51144-0050-01 - brentuximab vedotin REC Injection | $378,052 | $102,074 | — | — | 13 |
| 108329173-2255351 | 71336-1001-01 - givosiran 189 mg/mL Soln | $354,900 | $95,823 | — | — | 9 |
| 108329173-2255351 | 71336-1001-01 - givosiran 189 mg/mL Soln | $354,900 | $95,823 | — | — | 13 |
| 95181033-2255347 | 50242-0917-01 - atezolizumab 1200 mg/20 mL Soln | $354,271 | $95,653 | — | — | 9 |
| 95181033-2255347 | 50242-0917-01 - atezolizumab 1200 mg/20 mL Soln | $354,271 | $95,653 | — | — | 13 |
| 108028150-2255347 | 68727-0745-02 - cytarabine liposomal-daunorubicin | $340,712 | $91,992 | — | — | 9 |
| 108028150-2255347 | 68727-0745-02 - cytarabine liposomal-daunorubicin | $340,712 | $91,992 | — | — | 13 |
| 102633516-2255347 | 61755-0008-01 - cemiplimab 350 mg/7 mL Soln | $333,961 | $90,169 | — | — | 9 |
| 102633516-2255347 | 61755-0008-01 - cemiplimab 350 mg/7 mL Soln | $333,961 | $90,169 | — | — | 13 |
| 97775451-2120379 | DEVICE VENTRICULAR ASSIST CARDIAC 14086-2550-000[I | $328,000 | $88,560 | — | — | 9 |
| 97775451-2120379 | DEVICE VENTRICULAR ASSIST CARDIAC 14086-2550-000[I | $328,000 | $88,560 | — | — | 13 |
Showing top 50 of 88,358 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.